Methyprylon is a sedative of the piperidinedione derivative family that was previously used for the treatment of insomnia. However, with the introduction of newer drugs with fewer side effects, such... Methyprylon was withdrawn from the U.S. market in June 1965 and the Canadian market in September 1990 due to adverse events.
- Mechanism
- Curator reviewed
Methyprylon binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
- Primary indication
- For the treatment of insomnia.Curator reviewed
- Formula / weight
- C10H17NO2 · 183.2475 g/mol (avg)
- Also known as
- Metiprilon · Metiprilone
- Code names
- Dea No. 2575 · Ro 1-6463
Resolves to
SIDLZWOQUZRBRU-UHFFFAOYSA-NSMILESCCC1(CC)C(=O)NCC(C)C1=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Methyprylon, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account